Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Buy
58
CCAP Quote, Financials, Valuation and Earnings
Last price:
$19.55
Seasonality move
:
4.73%
Day range:
$19.29 - $19.67
52-week range:
$15.91 - $20.03
Dividend yield:
9.88%
P/E ratio:
7.63x
P/S ratio:
6.96x
P/B ratio:
0.97x
Volume:
110.9K
Avg. volume:
111.8K
1-year change:
12.3%
Market cap:
$724.4M
Revenue:
$92.5M
EPS (TTM):
$2.56
Analysts' Opinion
-
Consensus RatingCrescent Capital BDC has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Crescent Capital BDC has an estimated upside of 0.62% from its current price of $19.55.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $19.55.
Fair Value
-
According to the consensus of 0 analysts, Crescent Capital BDC has 0.62% upside to fair value with a price target of -- per share.
CCAP vs. S&P 500
-
Over the past 5 trading days, Crescent Capital BDC has underperformed the S&P 500 by -0.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Crescent Capital BDC does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Crescent Capital BDC revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Crescent Capital BDC reported revenues of $18.1M.
Earnings Growth
-
Crescent Capital BDC earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Crescent Capital BDC reported earnings per share of $0.41.
Enterprise value:
1.6B
EV / Invested capital:
0.97x
Price / LTM sales:
6.96x
EV / EBIT:
10.08x
EV / Revenue:
15.02x
PEG ratio (5yr expected):
0.12x
EV / Free cash flow:
16.23x
Price / Operating cash flow:
7.52x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
5.77%
Net Income Margin (TTM):
90.75%
Return On Equity:
12.68%
Return On Invested Capital:
5.91%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $32.6M | $64.2M | $104.2M | $25M | $18.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | $0.84 | $1.54 | $2.56 | $0.61 | $0.41 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.6M | $31.3M | $33.9M | $40.8M | $29.3M | |
| Total Assets | $980.5M | $1.2B | $1.3B | $1.6B | $1.6B | |
| Current Liabilities | $16.5M | $26.1M | $25.8M | $32.5M | $34.7M | |
| Total Liabilities | $443.4M | $587M | $716.7M | $894.2M | $896.2M | |
| Total Equity | $537.1M | $596.2M | $622.6M | $730.3M | $748.8M | |
| Total Debt | $422.2M | $557.1M | $686.1M | $856.7M | $857.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$127.7M | $99.5M | $96.4M | $21.4M | $46.9M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $130.3M | -$98.9M | -$81.4M | -$20M | -$45.3M | |
| Free Cash Flow | -$127.7M | $99.5M | $96.4M | $21.4M | $46.9M | |
CCAP
Sector
Market Cap
$724.4M
$694.9M
Price % of 52-Week High
97.58%
87.97%
Dividend Yield
9.88%
2.23%
Shareholder Yield
--
3.88%
1-Year Price Total Return
12.3%
8.55%
Beta (5-Year)
--
0.737
Dividend yield:
9.88%
Annualized payout:
$1.81
Payout ratio:
79.99%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$19.65
200-day SMA
Buy
Level
$18.31
Bollinger Bands (100)
Buy
Level
18.02 - 19.18
Chaikin Money Flow
Sell
Level
-4.2M
20-day SMA
Buy
Level
$19.51
Relative Strength Index (RSI14)
Buy
Level
56.12
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-60.3309
50-day SMA
Buy
Level
$18.89
MACD (12, 26)
Buy
Level
0.19
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
5.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.5769)
Buy
CA Score
(Annual)
Level (-0.1858)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (0.1121)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
Stock Forecast FAQ
In the current month, CCAP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CCAP average analyst price target in the past 3 months is --.
-
Where Will Crescent Capital BDC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Crescent Capital BDC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Crescent Capital BDC?
Analysts are divided on their view about Crescent Capital BDC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Crescent Capital BDC is a Sell and believe this share price will drop from its current level to --.
-
What Is Crescent Capital BDC's Price Target?
The price target for Crescent Capital BDC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CCAP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Crescent Capital BDC is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CCAP?
You can purchase shares of Crescent Capital BDC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Crescent Capital BDC shares.
-
What Is The Crescent Capital BDC Share Price Today?
Crescent Capital BDC was last trading at $19.55 per share. This represents the most recent stock quote for Crescent Capital BDC. Yesterday, Crescent Capital BDC closed at $19.55 per share.
-
How To Buy Crescent Capital BDC Stock Online?
In order to purchase Crescent Capital BDC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Lucid vs Rivian Stock: Which Is Best?
Few realize that Lucid Group (NASDAQ: LCID) traces part of…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
